New Zealand - engelsk - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin;   - injection (depot) - 10.8 mg - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin   excipient: polyglactin - zoladex 10.8 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - sacubitril/valsartan 100mg (as sodium hydrate complex, contains 48.6 mg sacubitril and 51.4 mg valsartan);  ;   - film coated tablet - 48.6 mg/51.4 mg - active: sacubitril/valsartan 100mg (as sodium hydrate complex, contains 48.6 mg sacubitril and 51.4 mg valsartan)     excipient: colloidal silicon dioxide crospovidone hyprolose basic coating premix, white basic coating premix, yellow basic coating premix, red magnesium stearate microcrystalline cellulose purified talc purified water - entresto is indicated in adult patients with chronic heart failure (nyha class ii-iv). benefits are most clearly evident in patients with left ventricular ejection fraction (lvef) below normal. lvef is a variable measure, so use clinical judgment in deciding whom to treat

Canada - engelsk - Health Canada

tanning research laboratories, inc. - octocrylene; oxybenzone; avobenzone - spray - 10.0%; 5.0%; 3.0% - octocrylene 10.0%; oxybenzone 5.0%; avobenzone 3.0% - sunscreen agents

Canada - engelsk - Health Canada

energizer canada inc - octocrylene; oxybenzone; avobenzone - spray - 10%; 5%; 3% - octocrylene 10%; oxybenzone 5%; avobenzone 3% - sunscreen agents

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - sacubitril/valsartan 200mg (as sodium hydrate complex, contains 97.2 mg sacubitril and 102.8 mg valsartan);  ;   - film coated tablet - 97.2 mg/102.8 mg - active: sacubitril/valsartan 200mg (as sodium hydrate complex, contains 97.2 mg sacubitril and 102.8 mg valsartan)     excipient: colloidal silicon dioxide crospovidone hyprolose basic coating mixture, white basic coating mixture, red basic coating mixture, black magnesium stearate microcrystalline cellulose purified talc purified water - entresto is indicated in adult patients with chronic heart failure (nyha class ii-iv). benefits are most clearly evident in patients with left ventricular ejection fraction (lvef) below normal. lvef is a variable measure, so use clinical judgment in deciding whom to treat

Canada - engelsk - Health Canada

tanning research laboratories, inc. - homosalate; octinoxate; oxybenzone; octisalate; octocrylene - lotion - 8.00%; 7.50%; 6.00%; 5.00%; 2.00% - homosalate 8.00%; octinoxate 7.50%; oxybenzone 6.00%; octisalate 5.00%; octocrylene 2.00% - sunscreen agents

Canada - engelsk - Health Canada

prime enterprises, llc. - avobenzone; ensulizole; homosalate; octisalate; octocrylene; oxybenzone - spray - 3.0%; 1.0%; 10.0%; 5.0%; 2.5%; 4.0% - avobenzone 3.0%; ensulizole 1.0%; homosalate 10.0%; octisalate 5.0%; octocrylene 2.5%; oxybenzone 4.0% - sunscreen agents

Canada - engelsk - Health Canada

vital science a div. of/une div. de valeant canada ltd/ltee - avobenzone; homosalate; octisalate; octocrylene; oxybenzone - cream - 3%; 15%; 5%; 10%; 6% - avobenzone 3%; homosalate 15%; octisalate 5%; octocrylene 10%; oxybenzone 6% - sunscreen agents

Canada - engelsk - Health Canada

laboratoires dermo-cosmetik inc - avobenzone; homosalate; octisalate; octocrylene - cream - 3%; 15%; 5%; 10% - avobenzone 3%; homosalate 15%; octisalate 5%; octocrylene 10% - sunscreen agents

Canada - engelsk - Health Canada

prime enterprises, llc. - avobenzone; homosalate; octisalate; octocrylene; oxybenzone - lotion - 3%; 10%; 5%; 2.75%; 4% - avobenzone 3%; homosalate 10%; octisalate 5%; octocrylene 2.75%; oxybenzone 4% - sunscreen agents